ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.

IF 4.1 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2024-12-05 Epub Date: 2024-10-30 DOI:10.1128/aac.01127-24

Michael R Jacobs, Caryn E Good, Ayman M Abdelhamed, Andrew R Mack, Christopher R Bethel, Steven H Marshall, Andrea M Hujer, Kristine M Hujer, Robin Patel, David van Duin, Vance G Fowler, Daniel D Rhoads, David A Six, Greg Moeck, Tsuyoshi Uehara, Krisztina M Papp-Wallace, Robert A Bonomo

{"title":"ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.","authors":"Michael R Jacobs, Caryn E Good, Ayman M Abdelhamed, Andrew R Mack, Christopher R Bethel, Steven H Marshall, Andrea M Hujer, Kristine M Hujer, Robin Patel, David van Duin, Vance G Fowler, Daniel D Rhoads, David A Six, Greg Moeck, Tsuyoshi Uehara, Krisztina M Papp-Wallace, Robert A Bonomo","doi":"10.1128/aac.01127-24","DOIUrl":null,"url":null,"abstract":"Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with ceftibuten for the treatment of urinary tract infections. At ceftibuten breakpoints of ≤1 mg/L (EUCAST) and ≤8 mg/L (CLSI), 92.5% and 99.0%, respectively, of 200 carbapenem-resistant Klebsiella pneumoniae isolates, predominantly K. pneumoniae carbapenemase producing, were susceptible to ceftibuten-ledaborbactam (ledaborbactam tested at a fixed concentration of 4 mg/L) compared to 4.5% and 30.5%, respectively, to ceftibuten alone.","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0112724"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619242/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01127-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with ceftibuten for the treatment of urinary tract infections. At ceftibuten breakpoints of ≤1 mg/L (EUCAST) and ≤8 mg/L (CLSI), 92.5% and 99.0%, respectively, of 200 carbapenem-resistant Klebsiella pneumoniae isolates, predominantly K. pneumoniae carbapenemase producing, were susceptible to ceftibuten-ledaborbactam (ledaborbactam tested at a fixed concentration of 4 mg/L) compared to 4.5% and 30.5%, respectively, to ceftibuten alone.

查看原文本刊更多论文

ARGONAUT-IV：产碳青霉烯酶肺炎克雷伯氏菌对口服双环硼酸酯β-内酰胺酶抑制剂 ledaborbactam 联合头孢布烯的敏感性。

来达巴坦（原名 VNRX-5236）是一种双环硼酸酯类 β-内酰胺酶抑制剂，对 A、C 和 D 类 β-内酰胺酶具有活性，目前正在开发一种口服生物可利用的 etzadroxil 原药 (VNRX-7145)，与头孢布烯联用治疗尿路感染。在头孢布坦断点≤1 mg/L（EUCAST）和≤8 mg/L（CLSI）时，200 株耐碳青霉烯类的肺炎克雷伯菌分离株（主要是产碳青霉烯酶的肺炎克雷伯菌）中分别有 92.5% 和 99.0% 对头孢布坦-领博巴坦敏感（领博巴坦的测试浓度固定为 4 mg/L），而单独使用头孢布坦的敏感率分别为 4.5% 和 30.5%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.